Download PDF
Semin Thromb Hemost 2016; 42(03): 252-257
DOI: 10.1055/s-0035-1570080
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelets in Critical Illness

Marcel Levi
1   Department of Medicine, Academic Medical Centre, Meibergdreef, AZ Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
29 February 2016 (online)

    Permissions and Reprints

Abstract

In patients with critical illness, thrombocytopenia is a frequent laboratory abnormality. However frequent this may occur, a low platelet count is not an epiphenomenon, but a marker with further significance. It is always important to assess the proper cause for thrombocytopenia in critically ill patients because different underlying disorders may precipitate different diagnostic and therapeutic management strategies. Platelets are part of the first-line defense of the body against bleeding; hence, thrombocytopenia may increase the risk of hemorrhage. In case of systemic inflammatory syndromes, such as the response to sepsis, disseminated intravascular platelet activation may occur. This will contribute to microvascular failure and thereby play a role in the development of organ dysfunction. Platelets are circulating blood cells that will normally not interact with the intact vessel wall but that may swiftly respond to endothelial disruption (which is often part of the pathogenesis of critical illness) by adhering to subendothelial structures, followed by interaction with each other, thereby forming a platelet aggregate. The activated platelet (phospholipid) membrane may form a suitable surface on which further coagulation activation may occur. A low platelet count is a strong and independent predictor of an adverse outcome in critically ill patients, thereby facilitating a simple and practically risk assessment in these patients and potentially guiding the use of complex or expensive treatment strategies.

Keywords

platelets - coagulation - intensive care - sepsis - disseminated intravascular coagulation - thrombotic microangiopathy - immune thrombocytopenia
 

  • References

  • 1 Levi M. Platelets. Crit Care Med 2005; 33 (12, Suppl): S523-S525
    CrossrefPubMedGoogle Scholar
  • 2 Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10 (4) 222
    CrossrefPubMedGoogle Scholar
  • 3 Levi M. Thrombosis and hemostasis issues in critically ill patients. Semin Thromb Hemost 2015; 41 (1) 7-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Vanderschueren S, De Weerdt A, Malbrain M , et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28 (6) 1871-1876
    CrossrefPubMedGoogle Scholar
  • 5 Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest 1993; 104 (4) 1243-1247
    CrossrefPubMedGoogle Scholar
  • 6 Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30 (8) 1765-1771
    CrossrefPubMedGoogle Scholar
  • 7 Stéphan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999; 115 (5) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 8 Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997; 31 (3) 285-289
    PubMedGoogle Scholar
  • 9 Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30 (4) 753-756
    CrossrefPubMedGoogle Scholar
  • 10 Löwenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010; 68 (6) 242-251
    PubMedGoogle Scholar
  • 11 Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999; 25 (1) 63-67
    CrossrefPubMedGoogle Scholar
  • 12 Levi M, Sivapalaratnam S. Hemostatic abnormalities in critically ill patients. Intern Emerg Med 2015; 10 (3) 287-296
    CrossrefPubMedGoogle Scholar
  • 13 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2, Suppl): S26-S34
    CrossrefPubMedGoogle Scholar
  • 14 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (8) 589-600
    CrossrefPubMedGoogle Scholar
  • 15 Tsai HM. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003; 23 (3) 388-396
    CrossrefPubMedGoogle Scholar
  • 16 van den Born BJ, van der Hoeven NV, Groot E , et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008; 51 (4) 862-866
    CrossrefPubMedGoogle Scholar
  • 17 Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost 2015; 41 (1) 49-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23 (6) 745-753
    CrossrefPubMedGoogle Scholar
  • 19 Warkentin TE, Levine MN, Hirsh J , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-1335
    CrossrefPubMedGoogle Scholar
  • 20 Selleng K, Selleng S, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Semin Thromb Hemost 2008; 34 (5) 425-438
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4 (4) 759-765
    CrossrefPubMedGoogle Scholar
  • 22 Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120 (20) 4160-4167
    CrossrefPubMedGoogle Scholar
  • 23 Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart 2001; 86 (6) E18
    CrossrefPubMedGoogle Scholar
  • 24 Levi M. Platelets in sepsis. Hematology 2005; 10 (Suppl. 01) 129-131
    CrossrefPubMedGoogle Scholar
  • 25 Folman CC, Linthorst GE, van Mourik J , et al. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis?. Thromb Haemost 2000; 83 (6) 923-930
    PubMedGoogle Scholar
  • 26 François B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997; 103 (2) 114-120
    CrossrefPubMedGoogle Scholar
  • 27 Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program) 2003; •••: 497-519
    PubMedGoogle Scholar
  • 28 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341 (8) 586-592
    CrossrefPubMedGoogle Scholar
  • 29 Levin J, Poore TE, Young NS , et al. Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med 1972; 76 (1) 1-7
    CrossrefPubMedGoogle Scholar
  • 30 Zielinski T, Wachowicz B, Saluk-Juszczak J, Kaca W. Polysaccharide part of Proteus mirabilis lipopolysaccharide may be responsible for the stimulation of platelet adhesion to collagen. Platelets 2002; 13 (7) 419-424
    CrossrefPubMedGoogle Scholar
  • 31 Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30 (5, Suppl): S294-S301
    CrossrefPubMedGoogle Scholar
  • 32 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300 (3) 729-735
    CrossrefPubMedGoogle Scholar
  • 33 Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (1) 327-358
    CrossrefPubMedGoogle Scholar
  • 34 Levi M, Löwenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost 2008; 34 (5) 417-424
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007; ;11 Suppl 5: S3
    PubMedGoogle Scholar
  • 36 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M ; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (5) 1327-1330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32 (12) 2416-2421
    CrossrefPubMedGoogle Scholar
  • 38 Dhainaut JF, Yan SB, Joyce DE , et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2 (11) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 39 Bockmeyer CL, Claus RA, Budde U , et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93 (1) 137-140
    CrossrefPubMedGoogle Scholar
  • 40 Eerenberg ES, Levi M. The potential therapeutic benefit of targeting ADAMTS13 activity. Semin Thromb Hemost 2014; 40 (1) 28-33
    PubMedGoogle Scholar
  • 41 Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86 (9) 743-751
    CrossrefPubMedGoogle Scholar
  • 42 Levi M, van der Poll T. Endothelial injury in sepsis. Intensive Care Med 2013; 39 (10) 1839-1842
    CrossrefPubMedGoogle Scholar
  • 43 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (9) 2730-2735
    CrossrefPubMedGoogle Scholar
  • 44 Thiele T, Selleng K, Selleng S, Greinacher A, Bakchoul T. Thrombocytopenia in the intensive care unit-diagnostic approach and management. Semin Hematol 2013; 50 (3) 239-250
    CrossrefPubMedGoogle Scholar
  • 45 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
    CrossrefPubMedGoogle Scholar
  • 46 Levi M, Toh CH, Thachil J, Watson HG ; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (1) 24-33
    CrossrefPubMedGoogle Scholar
  • 47 Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004; 164 (4) 361-369
    CrossrefPubMedGoogle Scholar